December 13, 2006 – Vertex released very strong interim data on telaprevir, its much-hyped protease inhibitor for hepatitis C; Icos will lay off its 700 employees if the merger with Lilly is approved; Exact Sciences reported its stool-based screening test was 88% effective in detecting colorectal cancer; Celgene said Barr Pharma is seeking approval of a generic equivalent to Thalomid; Keryx began a Phase II trial to test a drug for rare sarcomas; Crucell put its rabies treatment into a Phase I study; Indevus reported the FDA accepted its application for approval of Sanctura XR; Pain Therapeutics began a Phase III test of Oxytrex, a treatment for severe chronic pain; and the FDA asked Pozen for more information on migraine drug Trexima. The Centient Biotech 200™ fell 32 points to 3940, a loss of .82%. More details...
